Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma.
Shares in Scancell were up.
Shares of Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) jumped 23% in early trading following the announcement that the initial stage of its phase II SCOPE.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)’s expectation-busting initial results from the phase II SCOPE trial in advanced melanoma backs Stifel’s view.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious diseases, has announced the immediate appointment.